期刊文献+

糖尿病肾病患者血浆NGAL和血清CysC水平改变及其早期诊断价值 被引量:12

Changes of Serum NGAL and CysC Levels in Patients with Diabetic Nephropathy and Their Early Diagnostic Value
原文传递
导出
摘要 目的:研究糖尿病肾病(DN)患者血浆中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和血清胱抑素C(CysC)水平变化,分析其对DN的早期诊断价值。方法:选取160例糖尿病(DM)患者按尿微量白蛋白排泄率(UAER)分为DN前期组58例(A组),DN早期组52例(B组)及DN临床组50例(C组),同期选择健康体检者61例为对照组(D组)。比较四组受试者血中NGAL、CysC、尿素氮(BUN)和血肌酐(CREA),及尿中微量清蛋白(UMA)水平的差异,分析血NGAL、CysC与UMA之间的相关关系。结果:(1)A、B、C组受试者NGAL、CysC及UMA水平显著高于D组,且C>B>A,差异均有统计学意义(P<0.05);C组BUN和CREA水平均明显高于A、B、D三组,差异均有统计学意义(P<0.05),而A、B组较D组均无统计学差异(P>0.05)。(2)血NGAL、CysC与尿UMA均存在正相关关系(r=0.59,0.64;P均<0.05)。结论:DN早期患者血浆NGAL与血清CysC水平显著升高,且二者均与尿UMA水平存在正相关关系,可作为评价肾脏损害程度及DN早期诊断的较敏感的生物学标志物,临床推荐应用。 Objective: To study the changes of serum neutrophil gelatinase-associated lipocalin(NGAL)and cystatin C(CysC)levels in patients with diabetic nephropathy(DN), and their value of diagnosis for early DN. Methods: A total of 160 patients with diabetes mellitus(DM) were selected and divided into before DN group(group A, n=58), early DN group(group B, n=52) and clinical DN group(group C, n=50) according to the different levels of urinary albumin excretion rates(UAER), in the same period, 61 healthy persons were chosen as control group(group D). The levels of serum NGAL, CysC, blood urea nitrogen(BUN), serum creatinine(CREA), and urinary microalbumin(UMA) in the four groups were compared; the correlation of serum NGAL and CysC with UMA was analyzed.Results: The levels of serum NGAL, CysC, and UMA in group A, B and C were significantly higher than that in group D, and the levels of the above indexes in group C were higher than those in group B, the levels of the above indexes in group B were higher than those in group A, the differences were statistically significant(P〈0.05). The levels of BUN and CREA in group C were significantly higher than those in group A, B and D, the differences were statistically significant(P〈0.05), but there was no significant difference among group A,B and D(P〈0.05). The levels of serum NGAL and CysC were positively correlated with the levels of UMA(r=0.59, 0.64; P〈0.05).Conclusion: The levels of serum NGAL and CysC significantly increase in the patients with early DN and are positively correlated with the levels of UMA, which can be used as the sensitive biomarkers for evaluating the degree of renal damage and diagnosis of early DN and is worthy of clinical application.
机构地区 陕西省核工业
出处 《现代生物医学进展》 CAS 2015年第30期5945-5947,5900,共4页 Progress in Modern Biomedicine
关键词 糖尿病肾病 中性粒细胞明胶酶相关脂质运载蛋白 血清胱抑素C 尿微量白蛋白排泄率 Diabetic nephropathy Neutrophil gelatinase-associated lipocalin Serum cystatin C Urinary albumin excretion rate
  • 相关文献

参考文献20

  • 1Chen H,Wei F,Wang L,et al.MTHFR gene C677T polymorphism and type 2 diabetic nephropathy in Asian populations:a meta-analysis[J].Int J Clin Exp Med,2015,8(3):3662-3670.
  • 2Perlman AS,Chevalier JMj Wilkinson P,et al.Serum Inflammatoiy and Immune Mediators Are Elevated in Early Stage Diabetic Nephropathy[J].Ann Clin Lab Sci,2015,45(3):256-263.
  • 3Dimas G,Iliadis F,Tegos T,et al.4B.08:Serum Levels of TIMP-1 and IL-6 are Associated with Hypertension and Atherosclerosis in Patients with Early Stages of Chronic Kidney Disease and Type 2 Diabetic Nephropathy[J].J Hypertens,2015,33(Suppl 1):e55.
  • 4Dimas G,Iliadis F,Tegos T,et al.4A.05:CirculatingFGF-23 as an Independent Correlate of Hypertension and Atherosclerosis in Early Stages of CKD[J].J Hypertens,2015,33(Suppl I):e50.
  • 5Chen HH,Anstrom KJ,Givertz MM,et al.Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction:the ROSE acute heart failure randomized trial[J].Jama,2013,310(23):2533-2543.
  • 6Katagiri D,Doi K,Matsubara T,et al.New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury[J].J Crit Care,2013,28(5):564-570.
  • 7Urbschat A,Gauer S,Paulus P,et al.Serum and urinary NGAL but not KIM-1 raises in human postrenal AKI[J].Eur J Clin Invest,2014,44(12):652-659.
  • 8张伟,程丰.尿微量白蛋白、血清胱抑素C和β2微球蛋白联合检测对糖尿病肾病早期诊断的价值[J].临床血液学杂志(输血与检验),2014,27(6):1025-1027. 被引量:21
  • 9刘圣,陈象青,唐丽琴,余娜,张小力,杜红芳.复方黄连胶囊对早期糖尿病肾病大鼠肾组织TGF-β1/BMP-7表达失衡及其Smad信号通路的调控作用[J].中国中药杂志,2015,40(5):938-945. 被引量:31
  • 10Wang S,Wang Y,Zheng R,et al.Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy[J].Int J Clin Exp Pathol,2015,8(3):3110-3115.

二级参考文献44

  • 1张淑芳,汪海东,曹春玲,王丽.老年2型糖尿病患者尿微量白蛋白与C反应蛋白及胰岛素抵抗关系的临床观察[J].中国医学工程,2005,13(1):20-21. 被引量:26
  • 2程苏琴,朱美财.尿微量白蛋白在糖尿病肾损伤早期诊断中的价值[J].中华检验医学杂志,2005,28(7):740-741. 被引量:203
  • 3李培敏,陶庆枢.血清胱抑素C与超敏C反应蛋白联检诊断早期糖尿病肾损伤的价值[J].现代医院,2007,7(4):19-19. 被引量:34
  • 4Kjeldsen L,Johnsen AH,Sengelov H,et al.Isolation and primary structure of NGAL,a novel protein associated with human neutrophil gelatinase.J Biol Chem,1993,268(14):10425-10432.
  • 5Tong Z,Wu X,Ovcharenko D,et al.Neutrophil gelatinase-associated lipocalin as a survival factor.Biochem J,2005,391(Pt 2):441-448.
  • 6Borregaard N,Cowland JB.Neutrophil gelatinase-associated lipocalin,a siderophore-binding eukaryotic protein.Biometals,2006,19(2):211-215.
  • 7Flo TH,Smith KD,Sato S,et al.Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron.Nature,2004,432(7019):917-921.
  • 8Berger T,Togawa A,Duncan GS,et al.Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury.Proc Natl Acad Sci U S A,2006,103(6):1834-1839.
  • 9Yang J,Goetz D,Li JY,et al.An iron delivery pathway mediated by a lipocalin.Mol Cell,2002,10(5):1045-1056.
  • 10Li JY,Ram G,Gast K,et al.Detection of intracellular iron by its regulatory effect.Am J Physiol Cell Physiol,2004,287(6):C1547-1559.

共引文献63

同被引文献114

  • 1丁雪梅.心肌肌钙蛋白及N-末端脑钠肽前体水平在老年慢性肾脏病中的变化及与预后的相关性[J].中国老年学杂志,2014,34(12):3314-3316. 被引量:6
  • 2杨霓芝,刘旭生.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8. 被引量:1181
  • 3陆再英,钟南山主编.内科学[M].北京:人民卫生出版社,2010:513-525.
  • 4Malyszko J. Mechanism of endothelial dysfimction in chronic kidney disease[J]. Clinica Chimica Acta, 2010, 411(19-20): 1412-1420.
  • 5Ghosh A K, Vaughan D E. PAI-1 in tissue fibrosis [J]. Journal of Cellular Physiology, 2012, 227(2): 493-507.
  • 6Kosehinsky M L, Marcovina S M. Structure-function relationships in apolipoprotein (a): insights into lipoprotein (a) assembly and pathogenicity[J]. Curr Opin Lipidol, 2004, 15(2): 167-174.
  • 7Dube J B, Boffa M B, Hegele R A, et al. Lipoprotein (a): more interesting than ever after 50 years[J]. Curr Opin Lipidol, 2012, 23(2): 133-140.
  • 8Fortenberry Y M. Plasminogen activator inhibitor-1 irthibitors: a patent review (2006-present)[J]. Expert Opin Ther Pat, 2013, 23(7): 801-815.
  • 9Doucet C, Mooser V, Gonbert S, et al. Lipoprotein (a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine [J]. J Am Soc Nephrol, 2000, 11 (3): 507-513.
  • 10Eddy A A, Fogo A B. Plasminogen activator inhibitor-1 in chronickidney disease: evidence and mechanisms of action [J]. J Am Soc Nephrol, 2006, 17(11): 2999-3012.

引证文献12

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部